EYLEA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

The Global Eylea Market is estimated to be valued at USD 838.6 Mn in 2025 and is expected to reach USD 673.7 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -3.1% from 2025 to 2032.

The global Eylea market, while a prominent player in the ophthalmology sector, is currently facing a period of decline. Despite its earlier success in revolutionizing the treatment of retinal vascular diseases like neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), the market is now experiencing a negative growth trend. This decline is primarily attributed to the emergence of alternative therapies, the high cost of Eylea, and the increasing competition from other anti-VEGF agents.

Market Dynamics

Several factors are contributing to the market’s downward trajectory. Although the prevalence of eye disorders and the growing geriatric population remain significant drivers of demand, the high price point of Eylea limits its accessibility, particularly in developing regions where alternative, more affordable options are becoming available. Furthermore, newer treatments are providing comparable efficacy, leading to increased market fragmentation.

Despite these challenges, there are still opportunities within the market. Ongoing research and development aimed at improving Eylea’s efficacy and exploring new drug delivery systems, such as sustained-release formulations, may mitigate some of the market's negative growth. Additionally, the expanding indications for Eylea, such as for retinal vein occlusion and choroidal neovascularization, offer some potential for market recovery.

Key Features of the Study

• This report provides an in-depth analysis of the global Eylea market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key player
• It profiles key players in the global Eylea market based on the following parameters: company highlights, product portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Regeneron Pharmaceuticals, Inc. and Bayer AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Eylea market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Eylea market

Market Segmentation

•  Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Retinopathy of Prematurity (ROP)
•  Dosage Strength Insights (Revenue, USD Mn, 2020 - 2032)
  • 2 mg
  • 4 mg
  • 8 Mg
• Packaging Insights (Revenue, USD Mn, 2020 - 2032)
  • Pre-filled Syringe
  • Vial
•  Patient Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Pediatric
  • Adult
  • Geriatric
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Regeneron Pharmaceuticals
  • Bayer AG